Indaptus Therapeutics, Inc.
INDPHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframePart of the healthcare sector, Indaptus Therapeutics, Inc. (INDP) is listed under Biotechnology. At a $421.0M market cap, Indaptus Therapeutics, Inc. ranks as a small-cap company within healthcare. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors.
Market Cap
$421.0M
Beta
0.97
P/E (TTM)
—
P/E (Fwd)
-2.27
EPS (TTM)
$-6.15
EPS (Fwd)
$-1.39
ROE
-318.0%
ROA
-98.1%
Cash
$11.6M
Total Debt
$0
Free CF
-$9.7M
52W Change
-11.0%
Annual Financials
Cash vs Debt
Where INDP stands vs its 150-day and 200-day moving averages
As of the October 15, 2026 close, INDP finished 2.64% below its 150-day moving average ($2.27) and 3.07% below its 200-day moving average ($2.28). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is INDP overbought or oversold?
At the October 15, 2026 close, INDP's RSI(14) was 22.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Indaptus Therapeutics, Inc. reports $11.6M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$9.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -318.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Indaptus Therapeutics, Inc. and its sector.